ArticleFood science & nutrition2026
A Multi-Target Approach to Colitis: Ergothioneine Promotes Recovery by Restoring the Intestinal Barrier, Reducing Inflammation, and Remodeling the Microbiota.
Article in Food science & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ergothioneine (EGT) is a naturally occurring sulfur-containing histidine derivative with antioxidant and anti-inflammatory properties. However, its protective role and potential mechanisms in intestinal inflammation remain insufficiently understood. The impact of EGT on colitis was assessed in the present study using two experimental systems: an LPS-induced inflammatory model in Caco-2 cells and a DSS-induced colitis model in mice. In vitro, Caco-2 cells were treated with LPS and different concentrations of EGT, followed by assessment of inflammatory cytokines and tight junction-related markers using ELISA, qRT-PCR, and immunofluorescence staining. In vivo, DSS-induced colitis mice received low-, medium-, or high-dose EGT, and disease activity, colon histopathology, serum inflammatory mediators, immunoglobulins, and gut microbiota composition were analyzed. EGT treatment attenuated LPS-induced inflammatory responses in Caco-2 cells and partially restored the expression and distribution of tight junction proteins, including ZO-1, Occludin, and Claudin-1. In DSS-induced colitis mice, EGT alleviated body weight loss, reduced disease activity index scores, improved colon shortening and histological injury, and decreased serum levels of TNF-α, IL-6, IL-1β, IgM, and IgA. Moreover, EGT partially reversed DSS-induced gut microbiota dysbiosis. Notably, high-dose EGT was associated with the enrichment of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.